DDInter1628 DDInter1711
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Haemorrhage
Haemorrhage {u} (Side Effect) is caused by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KLHL18
KLHL18 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) downregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Haemorrhage intracranial
Haemorrhage intracranial {u} (Side Effect) is caused by {v} (Compound) Cilostazol
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) upregulates KLHL18 (Gene) and KLHL18 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) downregulates DNAJB2 (Gene) and DNAJB2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) causes Haemorrhage intracranial (Side Effect) and Haemorrhage intracranial (Side Effect) is caused by Cilostazol (Compound) and Cilostazol may lead to a major life threatening interaction when taken with Stiripentol
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ruxolitinib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is bound by Simvastatin (Compound) and HMGCR (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol